>
Raw Milk At The Crossroads… Again
Obama's Pentagon Developed The COVID Attack Plan, Warns Dr. Peter McCullough
NATO's Attempted Assassination Of Slovakian Leader Signals Total Desperation, Warns Jack Posobie
Renowned Oncologist Drops Bombshell: Ivermectin Cures Cancer
A Staggering 19x Energy Jump in Capacitors May Be the Beginning of the End for Batteries
Telegram Disabled My Account. Good Riddance
China's floating nuke plants up South China Sea ante
'Tungsten wall' leads to nuclear fusion breakthrough
Matt Taibbi Uncensored: Finance A 'Street Scam'
This Bonkers 656-Foot 'AirYacht' Concept Can Transport 40 Guests Around the World
DR. BRYAN ARDIS | How Much Nicotine Should You Use? How It Can Heal Parkinson's and More...
Elon Musk's Neuralink begins clinical trials in Phoenix
Scientists Are Making Jet Fuel from Landfill Gas Aiming to Launch Circular Economy
The one-two punch provided by the novel approach could pave the way for earlier detection and more effective treatment of the disease.
With an average five-year survival rate of less than 10%, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer. It's also difficult to detect using conventional imaging methods, including positron emission tomography (PET) scans.
Now, researchers at Osaka University in Japan have developed a strategy for combatting this deadly cancer by combining therapeutics and diagnostics – 'theranostics' – into a single, integrated process.
The process developed by the researchers uses radioactive monoclonal antibodies (mAb) to target glypican-1 (GPC1), a protein highly expressed in PDAC tumors. GPC1 has been implicated in cancer cell proliferation, invasion, and metastasis, and high expression of the protein is a poor prognostic factor in some cancers, including pancreatic cancer.
"We decided to target GPC1 because it is overexpressed in PDAC but is only present in low levels in normal tissues," said Tadashi Watabe, the study's lead author.
The researchers injected human pancreatic cancer cells into mice, allowing them to develop into a full tumor. The xenograft mice were administered intravenous GPC1 mAb labeled with radioactive zirconium (89Zr) and observed for antitumor effects.
"We monitored 89Zr-GPC1 mAb internalization over seven days with PET scanning," said Kazuya Kabayama, the study's second author. "There was strong uptake of the mAb into the tumors, suggesting that this method could support tumor visualization. We confirmed that this was mediated by its binding to GPC1, as the xenograft model that had GPC1 expression knocked out showed significantly less uptake."